Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp is well-positioned for growth due to its promising vaccine candidates, particularly the shingles vaccine, which demonstrates vaccine response rates (VRR) comparable to Shingrix with significantly better tolerability. The company leverages its Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses, reinforcing the potential for its product candidates across various cancer indications and its established HEPLISAV-B vaccine. Additionally, the favorable results in immunogenicity and tolerability for its products indicate a strong competitive advantage, which is expected to drive continued revenue growth primarily from the sale of its CpG 1018 product and HEPLISAV-B.

Bears say

Dynavax Technologies faces a negative outlook primarily due to the inherent risks associated with its clinical development pipeline, specifically the potential failure of future candidates to meet efficacy or safety standards, which could hinder approval and commercialization. Additionally, the company may struggle to effectively commercialize its products in a competitive market landscape, which could undermine its revenue generation capabilities. Lastly, uncertainties regarding the ability to secure acceptable partnership terms for its candidates further elevate the risks surrounding the successful launch and market penetration of its proprietary therapies.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.